Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma

This study has been completed.
Information provided by (Responsible Party):
Geron Corporation Identifier:
First received: July 16, 2008
Last updated: December 22, 2015
Last verified: December 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: October 2011
  Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)